
The result is fewer futile surgeries and improved predictive ability to determine response to somatostatin receptor-mediated therapies, including PRRT4.Ī review of three separate patient case studies found that the improved sensitivity uncovered a larger disease burden.
/arc-anglerfish-arc2-prod-sfr.s3.amazonaws.com/public/MI4MLEIH4JDHRIQZAX4BL465FA.jpg)
This equates to vastly improved imaging that helps clinicians detect 30% more lesions than Octreoscan, resulting in 71% of patients undergoing a change in their disease management. This PET imaging agent provides improved sensitivity and accuracy in addition to providing 100 times more affinity for somatostatin receptors than Octreoscan. NETSPOT provides a significant improvement over traditional diagnostic tools. NETSPOT ( 68Ga-Dotatate), an approved PET/CT imaging agent, is used for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients (2). The results from the completed examinations also provide clinicians with information that is quantitative and qualitative, which allows for improved lesion monitoring.Īs demonstrated by the data below (1), NETSPOT is the clear choice for providers and patients with NETs.Ĭompared to Octreotide, NETSPOT is 33.3% more sensitive, 14.6% more accurate, yields a 1.1% higher PPV and a 43.1% NPV. With NETSPOT ( 68Ga-Dotatate), the imaging process is completed within a few hours, does not involve any major prep and provides more definitive results than Octreotide. It usually has to be used with SPECT and CT. They describe OctreoScan as having “moderate sensitivity” as a stand-alone study and limitations in terms of tumor size.

Though if the abdomen is the area of interest, use of an over-the-counter laxative the night prior to imaging may minimize the amount of nonpathologic uptake in the bowel, as approximately 2% of the labeled somatostatin analog is cleared via the hepatobiliary system and will end up in the intestine.” For OctreoScan, patients need only to void prior to image acquisition.

“Long acting octreotide should be discontinued 4 to 6 weeks prior to imaging and the patient should be transitioned to a short acting regimen. The Octreotide and MIBG imaging often left referring physicians with unanswered questions while having the patient undergo multiple days of imaging and uncomfortable prep.įor example, here is the description of patient preparation a review published in the International Journal of Endocrinology Oncology: Until recently, providers relied heavily on the results of Octreotide (or Octreoscan) and MIBG scans for treatment guidance for somatostatin receptor-positive neuroendocrine tumors (NETs). The uptake of 68Ga-Dotatate reflects the level of somatostatin receptor density in neuroendocrine tumors. 68Ga-Dotatate, a positron-emitting analog of somatostatin, works by binding to such receptors. Neuroendocrine tumors have receptors for somatostatin, a hormone that regulates the endocrine system.

The tumors develop in the hormone-producing cells of the body’s neuroendocrine system, and are located in organs such as the stomach, intestines, pancreas, and lungs. Neuroendocrine tumors are malignant and benign tumors that affect an estimated 47,300 individuals in Europe and the United States each year. Here, we aim to answer a few key questions about NETSPOT and how it is used: Background on NETSPOT The commercial product is a single dose kit for the preparation of a 68Ga-Dotatate injection manufactured by Advanced Accelerator Applications of Saint Genis-Pouilly, France.įor PET imaging facilities who may be more used to using Octreotide or Octreoscan, NETSPOT may prove to be a good alternative. NETSPOT ( 68Ga-Dotatate) is a radioactive diagnostic agent used for PET imaging that is gaining ground among practices.įDA-approved in 2016, NETSPOT is used in imaging to locate somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients.
